Austria: Sanofi acquisition of Origimm Bio brings vaccine candidate for acne

France-headquartered global biopharmaceutical company, Sanofi, is to acquire Origimm Biotechnology an Austrian privately owned biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria causing skin disease. The transaction adds a potential first-in-class vaccine candidate in ‘acne vulgaris’ to Sanofi’s pipeline. The therapeutic vaccine candidate ‘ORI-001’ is based on recombinant…